167 related articles for article (PubMed ID: 30419769)
1. A case of severe, irreversible hypocalcemia after one dose of pamidronate administered for hypercalcemia of malignancy.
Kim S
J Oncol Pharm Pract; 2019 Oct; 25(7):1787-1793. PubMed ID: 30419769
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature.
Maalouf NM; Heller HJ; Odvina CV; Kim PJ; Sakhaee K
Endocr Pract; 2006; 12(1):48-53. PubMed ID: 16524863
[TBL] [Abstract][Full Text] [Related]
3. Pamidronate-induced irreversible symptomatic hypocalcemia in a dog with hypercalcemia after glucocorticoid withdrawal: a case report.
Oh YI; An JH; Lim GH; Park SM; Kim TH; Seo KW; Youn HY
BMC Vet Res; 2024 May; 20(1):227. PubMed ID: 38790012
[TBL] [Abstract][Full Text] [Related]
4. Successful Management of Severe Hypercalcemia with Zoledronic Acid: A Report of Two Pediatric Cases.
Kilci F; Jones JH; Çizmecioğlu-Jones FM
J Clin Res Pediatr Endocrinol; 2024 May; 16(2):224-228. PubMed ID: 36264042
[TBL] [Abstract][Full Text] [Related]
5. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
[TBL] [Abstract][Full Text] [Related]
6. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
7. Hypocalcemia following pamidronate administration for bone metastases of solid tumor: three clinical case reports.
Champallou C; Basuyau JP; Veyret C; Chinet P; Debled M; Chevrier A; Grongnet MH; Brunelle P
J Pain Symptom Manage; 2003 Feb; 25(2):185-90. PubMed ID: 12590034
[TBL] [Abstract][Full Text] [Related]
8. Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Mahmoud S; Mitwally H; El Zeer HS; El Madhoun I; Khatib M
Am J Case Rep; 2018 Sep; 19():1087-1089. PubMed ID: 30209247
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
10. [Pamidronate in the treatment of tumor-associated hypercalcemia].
Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tumor-induced osteolysis by APD.
Burckhardt P; Thiébaud D; Perey L; von Fliedner V
Recent Results Cancer Res; 1989; 116():54-66. PubMed ID: 2762665
[TBL] [Abstract][Full Text] [Related]
12. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy.
Major P
Oncologist; 2002; 7(6):481-91. PubMed ID: 12490736
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program.
Major PP; Coleman RE
Semin Oncol; 2001 Apr; 28(2 Suppl 6):17-24. PubMed ID: 11346861
[TBL] [Abstract][Full Text] [Related]
14. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism.
Jansson S; Tisell LE; Lindstedt G; Lundberg PA
Surgery; 1991 Sep; 110(3):480-6. PubMed ID: 1845370
[TBL] [Abstract][Full Text] [Related]
15. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate.
Wimalawansa SJ
Cancer; 1994 Apr; 73(8):2223-30. PubMed ID: 8156530
[TBL] [Abstract][Full Text] [Related]
16. Severe infantile hypercalcemia associated with Williams syndrome successfully treated with intravenously administered pamidronate.
Cagle AP; Waguespack SG; Buckingham BA; Shankar RR; Dimeglio LA
Pediatrics; 2004 Oct; 114(4):1091-5. PubMed ID: 15466114
[TBL] [Abstract][Full Text] [Related]
17. Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia.
Sims EC; Rogers PB; Besser GM; Plowman PN
Clin Oncol (R Coll Radiol); 1998; 10(6):407-9. PubMed ID: 9890546
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia and childhood cancer: a 7-year experience.
Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
[TBL] [Abstract][Full Text] [Related]
20. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
